Program
HLX3902
A development code.
In Fosun Pharma's pipeline, STEAP1 x CD3 x CD28
. Its studies are led by Fosun Pharma.
Furthest: phase 1, since Apr 2, 20261 company-led study, 1 open or runningNext primary completion: Jun 29, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 11 open or running | phase 1since Apr 2, 2026 | Apr 2, 2026 | Jun 29, 2027phase 1 · NCT07533708 |
- Named in Fosun Pharma’s own pipeline as
HLX3902 (STEAP1 x CD3 x CD28)
, phase 1, as of Sep 21, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 2, 2026First study: phase 1 study in mCRPC or Advanced/Metastatic Solid TumorsFirst studyNCT07533708 · 48 planned · China
Ahead
- Jun 29, 2027Primary completion: phase 1 study in mCRPC or Advanced/Metastatic Solid TumorsNCT07533708
TargetBeta
“STEAP1 x CD3 x CD28”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07533708mCRPC or Advanced/Metastatic Solid Tumors · China | 1 | Recruiting | Jun 29, 2027 | 48 |
How it is read
Names in the registry
- “HLX3902”, 1 entry
Codes read as this program: HLX3902.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.